Aethlon medical receives second ethics committee approval for hemopurifier® cancer trial

Bellberry human research ethics committee granted full ethics approval to the pindara private hospital for a safety, feasibility, and dose finding study of aethlon's hemopurifier® in patients with solid tumors not responding to anti-pd-1 antibodies san diego , aug. 12, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on august 6, 2024, the bellberry human research ethics committee (bhrec) granted full ethics approval to the pindara private hospital for a safety, feasibility and dose-finding clinical trial of the hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-pd-1 monotherapy treatment, such as merck's keytruda® (pembrolizumab) or bristol myers squibb's opdivo® (nivolumab) (aemd-2022-06 hemopurifier study). the approval is valid for one year, until august 6, 2025.
AEMD Ratings Summary
AEMD Quant Ranking